PMC:7074432 / 283-1119 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"24","span":{"begin":41,"end":96},"obj":"Species"},{"id":"25","span":{"begin":163,"end":174},"obj":"Species"},{"id":"26","span":{"begin":179,"end":201},"obj":"Species"},{"id":"27","span":{"begin":203,"end":212},"obj":"Species"},{"id":"28","span":{"begin":329,"end":338},"obj":"Species"},{"id":"29","span":{"begin":363,"end":371},"obj":"Species"},{"id":"30","span":{"begin":464,"end":467},"obj":"Species"},{"id":"31","span":{"begin":528,"end":531},"obj":"Species"},{"id":"32","span":{"begin":536,"end":544},"obj":"Species"},{"id":"33","span":{"begin":593,"end":602},"obj":"Species"},{"id":"35","span":{"begin":217,"end":236},"obj":"Disease"},{"id":"36","span":{"begin":238,"end":246},"obj":"Disease"},{"id":"37","span":{"begin":451,"end":460},"obj":"Disease"},{"id":"39","span":{"begin":620,"end":630},"obj":"Chemical"},{"id":"60","span":{"begin":715,"end":719},"obj":"Species"},{"id":"61","span":{"begin":732,"end":740},"obj":"Species"},{"id":"62","span":{"begin":756,"end":764},"obj":"Species"},{"id":"67","span":{"begin":638,"end":647},"obj":"Chemical"},{"id":"68","span":{"begin":651,"end":661},"obj":"Chemical"},{"id":"69","span":{"begin":783,"end":792},"obj":"Chemical"}],"attributes":[{"id":"A24","pred":"tao:has_database_id","subj":"24","obj":"Tax:1335626"},{"id":"A25","pred":"tao:has_database_id","subj":"25","obj":"Tax:11118"},{"id":"A26","pred":"tao:has_database_id","subj":"26","obj":"Tax:2697049"},{"id":"A27","pred":"tao:has_database_id","subj":"27","obj":"Tax:2697049"},{"id":"A28","pred":"tao:has_database_id","subj":"28","obj":"Tax:2697049"},{"id":"A29","pred":"tao:has_database_id","subj":"29","obj":"Tax:1335626"},{"id":"A30","pred":"tao:has_database_id","subj":"30","obj":"Tax:11118"},{"id":"A31","pred":"tao:has_database_id","subj":"31","obj":"Tax:11118"},{"id":"A32","pred":"tao:has_database_id","subj":"32","obj":"Tax:1335626"},{"id":"A33","pred":"tao:has_database_id","subj":"33","obj":"Tax:2697049"},{"id":"A35","pred":"tao:has_database_id","subj":"35","obj":"MESH:D018352"},{"id":"A36","pred":"tao:has_database_id","subj":"36","obj":"MESH:C000657245"},{"id":"A37","pred":"tao:has_database_id","subj":"37","obj":"MESH:D007239"},{"id":"A39","pred":"tao:has_database_id","subj":"39","obj":"MESH:D009705"},{"id":"A60","pred":"tao:has_database_id","subj":"60","obj":"Tax:11118"},{"id":"A61","pred":"tao:has_database_id","subj":"61","obj":"Tax:694009"},{"id":"A62","pred":"tao:has_database_id","subj":"62","obj":"Tax:9606"},{"id":"A67","pred":"tao:has_database_id","subj":"67","obj":"MESH:D012254"},{"id":"A68","pred":"tao:has_database_id","subj":"68","obj":"MESH:D009705"},{"id":"A69","pred":"tao:has_database_id","subj":"69","obj":"MESH:D012254"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"3 with epicenter in Guangdong, China,[2] Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012 in Saudi Arabia,[3] and the third epidemic of respiratory coronavirus the 2019-novel coronavirus (2019-nCoV) or coronavirus disease (COVID-19) mainly centered in Wuhan province, China.[4] The case fatalities vary from 2.5% (2019-nCoV),[5]10% (SARS), to 35% (MERS-CoV).[6] Till now, there is no approved antiviral or vaccine for the management of infection by CoV. However, from earlier experience of the management of SERS-CoV and MERS-CoV, many agents are being used in the treatment of 2019-nCoV.[7]\n\nAntivirals\n\nNucleoside analog\nRibavirin, a nucleoside analog, shows antiviral activity against some animal CoVs, and in the SARS-CoV epidemic, many patients were treated with ribavirin along with corticosteroids and became a sta"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T80","span":{"begin":620,"end":630},"obj":"CHEBI:33838;CHEBI:33838"},{"id":"T79","span":{"begin":638,"end":647},"obj":"DG_29"},{"id":"T78","span":{"begin":708,"end":714},"obj":"NCBITaxon:33208"},{"id":"T77","span":{"begin":732,"end":740},"obj":"SP_10"},{"id":"T76","span":{"begin":783,"end":792},"obj":"DG_29;CHEBI:28201;CHEBI:28201"},{"id":"T75","span":{"begin":804,"end":819},"obj":"CHEBI:50858;CHEBI:50858"},{"id":"T35","span":{"begin":41,"end":52},"obj":"SP_9"},{"id":"T34","span":{"begin":53,"end":64},"obj":"SP_9;UBERON:0001004"},{"id":"T33","span":{"begin":65,"end":85},"obj":"SP_9"},{"id":"T32","span":{"begin":87,"end":95},"obj":"SP_9"},{"id":"T31","span":{"begin":163,"end":174},"obj":"NCBITaxon:11118"},{"id":"T30","span":{"begin":190,"end":201},"obj":"NCBITaxon:11118"},{"id":"T29","span":{"begin":203,"end":212},"obj":"SP_7"},{"id":"T28","span":{"begin":217,"end":228},"obj":"NCBITaxon:11118"},{"id":"T27","span":{"begin":238,"end":246},"obj":"SP_7"},{"id":"T26","span":{"begin":329,"end":338},"obj":"SP_7"},{"id":"T25","span":{"begin":348,"end":352},"obj":"SP_10"},{"id":"T24","span":{"begin":363,"end":371},"obj":"SP_9"},{"id":"T23","span":{"begin":536,"end":544},"obj":"SP_9"},{"id":"T22","span":{"begin":551,"end":557},"obj":"CHEBI:52217;CHEBI:52217"},{"id":"T21","span":{"begin":593,"end":602},"obj":"SP_7"}],"text":"3 with epicenter in Guangdong, China,[2] Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012 in Saudi Arabia,[3] and the third epidemic of respiratory coronavirus the 2019-novel coronavirus (2019-nCoV) or coronavirus disease (COVID-19) mainly centered in Wuhan province, China.[4] The case fatalities vary from 2.5% (2019-nCoV),[5]10% (SARS), to 35% (MERS-CoV).[6] Till now, there is no approved antiviral or vaccine for the management of infection by CoV. However, from earlier experience of the management of SERS-CoV and MERS-CoV, many agents are being used in the treatment of 2019-nCoV.[7]\n\nAntivirals\n\nNucleoside analog\nRibavirin, a nucleoside analog, shows antiviral activity against some animal CoVs, and in the SARS-CoV epidemic, many patients were treated with ribavirin along with corticosteroids and became a sta"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T3","span":{"begin":238,"end":246},"obj":"Disease"},{"id":"T4","span":{"begin":348,"end":352},"obj":"Disease"},{"id":"T5","span":{"begin":451,"end":460},"obj":"Disease"},{"id":"T6","span":{"begin":732,"end":740},"obj":"Disease"}],"attributes":[{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"3 with epicenter in Guangdong, China,[2] Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012 in Saudi Arabia,[3] and the third epidemic of respiratory coronavirus the 2019-novel coronavirus (2019-nCoV) or coronavirus disease (COVID-19) mainly centered in Wuhan province, China.[4] The case fatalities vary from 2.5% (2019-nCoV),[5]10% (SARS), to 35% (MERS-CoV).[6] Till now, there is no approved antiviral or vaccine for the management of infection by CoV. However, from earlier experience of the management of SERS-CoV and MERS-CoV, many agents are being used in the treatment of 2019-nCoV.[7]\n\nAntivirals\n\nNucleoside analog\nRibavirin, a nucleoside analog, shows antiviral activity against some animal CoVs, and in the SARS-CoV epidemic, many patients were treated with ribavirin along with corticosteroids and became a sta"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1","span":{"begin":358,"end":360},"obj":"http://purl.obolibrary.org/obo/CLO_0001000"},{"id":"T2","span":{"begin":649,"end":650},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T3","span":{"begin":686,"end":694},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T4","span":{"begin":708,"end":714},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_33208"},{"id":"T5","span":{"begin":831,"end":832},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"3 with epicenter in Guangdong, China,[2] Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012 in Saudi Arabia,[3] and the third epidemic of respiratory coronavirus the 2019-novel coronavirus (2019-nCoV) or coronavirus disease (COVID-19) mainly centered in Wuhan province, China.[4] The case fatalities vary from 2.5% (2019-nCoV),[5]10% (SARS), to 35% (MERS-CoV).[6] Till now, there is no approved antiviral or vaccine for the management of infection by CoV. However, from earlier experience of the management of SERS-CoV and MERS-CoV, many agents are being used in the treatment of 2019-nCoV.[7]\n\nAntivirals\n\nNucleoside analog\nRibavirin, a nucleoside analog, shows antiviral activity against some animal CoVs, and in the SARS-CoV epidemic, many patients were treated with ribavirin along with corticosteroids and became a sta"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":408,"end":417},"obj":"Chemical"},{"id":"T2","span":{"begin":620,"end":630},"obj":"Chemical"},{"id":"T3","span":{"begin":649,"end":661},"obj":"Chemical"},{"id":"T4","span":{"begin":676,"end":685},"obj":"Chemical"},{"id":"T5","span":{"begin":783,"end":792},"obj":"Chemical"},{"id":"T6","span":{"begin":804,"end":819},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A2","pred":"chebi_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_33838"},{"id":"A3","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_33838"},{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_63580"},{"id":"A6","pred":"chebi_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"}],"text":"3 with epicenter in Guangdong, China,[2] Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012 in Saudi Arabia,[3] and the third epidemic of respiratory coronavirus the 2019-novel coronavirus (2019-nCoV) or coronavirus disease (COVID-19) mainly centered in Wuhan province, China.[4] The case fatalities vary from 2.5% (2019-nCoV),[5]10% (SARS), to 35% (MERS-CoV).[6] Till now, there is no approved antiviral or vaccine for the management of infection by CoV. However, from earlier experience of the management of SERS-CoV and MERS-CoV, many agents are being used in the treatment of 2019-nCoV.[7]\n\nAntivirals\n\nNucleoside analog\nRibavirin, a nucleoside analog, shows antiviral activity against some animal CoVs, and in the SARS-CoV epidemic, many patients were treated with ribavirin along with corticosteroids and became a sta"}

{"project":"LitCovid-sentences","denotations":[{"id":"T4","span":{"begin":469,"end":606},"obj":"Sentence"},{"id":"T5","span":{"begin":608,"end":618},"obj":"Sentence"},{"id":"T6","span":{"begin":620,"end":637},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"3 with epicenter in Guangdong, China,[2] Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012 in Saudi Arabia,[3] and the third epidemic of respiratory coronavirus the 2019-novel coronavirus (2019-nCoV) or coronavirus disease (COVID-19) mainly centered in Wuhan province, China.[4] The case fatalities vary from 2.5% (2019-nCoV),[5]10% (SARS), to 35% (MERS-CoV).[6] Till now, there is no approved antiviral or vaccine for the management of infection by CoV. However, from earlier experience of the management of SERS-CoV and MERS-CoV, many agents are being used in the treatment of 2019-nCoV.[7]\n\nAntivirals\n\nNucleoside analog\nRibavirin, a nucleoside analog, shows antiviral activity against some animal CoVs, and in the SARS-CoV epidemic, many patients were treated with ribavirin along with corticosteroids and became a sta"}